Wide Ranks

MGTX

MeiraGTx Holdings plc

6.55

Top Statistics
Market Cap 511 M Forward PE 7.89 Revenue Growth -92.00 %
Current Ratio 2.36 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.70 Enterprise / Revenue 51.69 Price To Sales Trailing12 Months 63.03
Profitability
Profit Margins 0.00 % Operating Margins -16279.79 %
Balance Sheet
Total Cash 99 M Total Cash Per Share 1.54 Total Debt 87 M
Total Debt To Equity 109.40 Current Ratio 2.36 Book Value Per Share 2.17
All Measures
Short Ratio 486.00 % Message Board Id finmb_404780252 Shares Short Prior Month 1 M
Return On Equity -0.9151 City New York Uuid 934d1a61-2bc1-31ce-acc9-153361189a8b
Previous Close 6.39 First Trade Date Epoch Utc 1 B Book Value 2.17
Beta 1.25 Total Debt 87 M Volume 233647
Price To Book 3.01 Fifty Two Week Low 3.85 Total Cash Per Share 1.54
Total Revenue 8 M Shares Short Previous Month Date 1 B Target Median Price 23.00
Audit Risk 2 Max Age 86400 Recommendation Mean 1.50
Sand P52 Week Change 0.3133 Operating Margins -16279.79 % Target Mean Price 23.25
Net Income To Common -93144000 Short Percent Of Float 0.0297 Implied Shares Outstanding 78 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 239860
Average Volume10days 239860 Total Cash 99 M Next Fiscal Year End 1 B
Revenue Per Share 0.1300 Held Percent Insiders 0.2425 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 7
Regular Market Previous Close 6.39 Target Low Price 11.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 5.44 Open 6.47 Free Cashflow -67232872
State NY Dividend Yield 0.00 % Return On Assets -0.3666
Time Zone Short Name EST Board Risk 3 Trailing Eps -1.20
Day Low 6.38 Address1 450 East 29th Street Shares Outstanding 78 M
Compensation Risk 9 Price Hint 2 Target High Price 36.00
Website https://meiragtx.com 52 Week Change 0.2548 Average Volume 286284
Forward Eps 0.8300 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 223.70 % Is_sp_500 False Regular Market Day High 6.62
Profit Margins 0.00 % Debt To Equity 109.40 Fifty Two Week High 7.60
Day High 6.62 Shares Short 1 M Regular Market Open 6.47
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 51.69
Revenue Growth -92.00 % Shares Percent Shares Out 0.0215 Operating Cashflow -95158000
Currency USD Time Zone Full Name America/New_York Market Cap 511 M
Is_nasdaq_100 False Zip 10016 Quote Type EQUITY
Industry Biotechnology Long Name MeiraGTx Holdings plc Overall Risk 6
Regular Market Day Low 6.38 Held Percent Institutions 0.5513 Current Price 6.55
Address2 14th Floor Enterprise To Ebitda -2.70 Financial Currency USD
Current Ratio 2.36 Gross Margins 100.00 % Industry Disp Biotechnology
Number Of Analyst Opinions 4 Country United States Float Shares 25 M
Two Hundred Day Average 5.12 Governance Epoch Date 1 B Enterprise Value 419 M
Price To Sales Trailing12 Months 63.03 Forward PE 7.89 Regular Market Volume 233647
Ebitda -155308992 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases.

The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.

Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial.

It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease.

The company was incorporated in 2015 and is based in New York, New York.